Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 3Active not recruiting 2Terminated 1Suspended 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Neoplasm Metastasis 4Leukemia, Myeloid, Acute 3Glioblastoma 3Breast Neoplasms 3Triple Negative Breast Neoplasms 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Pancreatic Neoplasms 2Osteosarcoma 2Myelodysplastic Syndromes 2Multiple Myeloma 2Lymphoma 2Glioma 2Carcinoma, Non-Small-Cell Lung 2Astrocytoma 2Urinary Bladder Neoplasms 1Thrombocythemia, Essential 1Sarcoma, Ewing 1Sarcoma 1Rhabdomyosarcoma 1Prostatic Neoplasms 1Primary Myelofibrosis 1Polycythemia Vera 1Ovarian Neoplasms 1Neuroblastoma 1Neoplasm, Residual 1Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Mesothelioma, Malignant 1Mesothelioma 1Melanoma 1

Interventions

Monatide (IMS 3015) 1Biological Assay 1ALT-803 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Suspended × NIH × Neoplasm, Residual × Clear all
NCT05642195 2026-06-05

Evaluation of a Cancer Lysate Vaccine and Montanide (Registered Trademark) ISA-51 VG With or Without the IL-15 Super-Agonist N-803 as Adjuvant Therapy for PD-L1 Negative Non-Small Cell Lung Cancer

National Institutes of Health Clinical Center (CC)

Phase 1/2 Suspended
30 enrolled
Thoracic

Carcinoma, Carcinoma, Non-Small-Cell Lung, Neoplasm, Residual

Data powered by HemOnc (CC BY 4.0) Colophon âš¡